Literature DB >> 17085794

Beta2-agonists for asthma: the pediatric perspective.

Padmaja Subbarao1, Felix Ratjen.   

Abstract

Inhaled beta-agonists are commonly prescribed for the treatment of wheezing disorders in infants and children. Despite this, there are concerns that these medications have potentially detrimental effects on lung health and symptoms. We will review the ontogeny of beta-agonist receptor and smooth muscle development from fetal life through infancy and childhood as well as the evidence supporting the clinical utility of beta-agonists in wheezing infants and asthmatic children. Finally, the potential detrimental effects of long- and short-acting beta-agonists in infants and children are discussed.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17085794     DOI: 10.1385/CRIAI:31:2:209

Source DB:  PubMed          Journal:  Clin Rev Allergy Immunol        ISSN: 1080-0549            Impact factor:   8.667


  75 in total

1.  One year treatment with salmeterol compared with beclomethasone in children with asthma. The Dutch Paediatric Asthma Study Group.

Authors:  A A Verberne; C Frost; R J Roorda; H van der Laag; K F Kerrebijn
Journal:  Am J Respir Crit Care Med       Date:  1997-09       Impact factor: 21.405

2.  Spontaneous contractility of human fetal airway smooth muscle.

Authors:  P B McCray
Journal:  Am J Respir Cell Mol Biol       Date:  1993-05       Impact factor: 6.914

3.  The efficacy of nebulized metaproterenol in wheezing infants and young children.

Authors:  A J Alario; W J Lewander; P Dennehy; R Seifer; A L Mansell
Journal:  Am J Dis Child       Date:  1992-04

4.  The administration of beta2-agonists for paediatric asthma and its adverse reaction in Australian and New Zealand emergency departments: a cross-sectional survey.

Authors:  Doaa Habashy; Lawrence T Lam; Gary J Browne
Journal:  Eur J Emerg Med       Date:  2003-09       Impact factor: 2.799

5.  Increased relaxation of immature airways to beta2-adrenoceptor agonists is related to attenuated expression of postjunctional smooth muscle muscarinic M2 receptors.

Authors:  Michael Fayon; Eric Dumas De La Roque; Patrick Berger; Hugues Begueret; Olga Ousova; Mathieu Molimard; Roger Marthan
Journal:  J Appl Physiol (1985)       Date:  2004-12-03

6.  Genetic polymorphisms of the beta 2-adrenergic receptor in nocturnal and nonnocturnal asthma. Evidence that Gly16 correlates with the nocturnal phenotype.

Authors:  J Turki; J Pak; S A Green; R J Martin; S B Liggett
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

7.  beta2 adrenoceptor Arg16Gly polymorphism, airway responsiveness, lung function and asthma in infants and children.

Authors:  S W Turner; S-K Khoo; I A Laing; L J Palmer; N A Gibson; P Rye; L I Landau; J Goldblatt; P N Le Souëf
Journal:  Clin Exp Allergy       Date:  2004-07       Impact factor: 5.018

8.  Oral and inhaled salbutamol in the prevention of exercise-induced bronchospasm.

Authors:  P W Francis; I R Krastins; H Levison
Journal:  Pediatrics       Date:  1980-07       Impact factor: 7.124

9.  Effects of nedocromil and salbutamol on airway reactivity in children with asthma.

Authors:  A Pfleger; E Eber; E Weinhandl; M S Zach
Journal:  Eur Respir J       Date:  2002-09       Impact factor: 16.671

10.  Wheezing in infants: the response to epinephrine.

Authors:  D I Lowell; G Lister; H Von Koss; P McCarthy
Journal:  Pediatrics       Date:  1987-06       Impact factor: 7.124

View more
  3 in total

1.  Vasculitis: current status and future directions.

Authors:  Pierre Youinou
Journal:  Clin Rev Allergy Immunol       Date:  2008-10       Impact factor: 8.667

2.  Cutting edge issues in autoimmunity.

Authors:  Yaniv Sherer; Torsten Matthias; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2008-06       Impact factor: 8.667

3.  S-Nitrosoglutathione Attenuates Airway Hyperresponsiveness in Murine Bronchopulmonary Dysplasia.

Authors:  Thomas M Raffay; Andrew M Dylag; Juliann M Di Fiore; Laura A Smith; Helly J Einisman; Yuejin Li; Mitchell M Lakner; Ahmad M Khalil; Peter M MacFarlane; Richard J Martin; Benjamin Gaston
Journal:  Mol Pharmacol       Date:  2016-08-02       Impact factor: 4.436

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.